Company intelligence / Profile preview
SciMar
Dauphin, Manitoba, Canadascimar.ca ↗
- Ownership
- Private
- Employees
- ~14
- Development stage
- Preclinical
01
Overview
SciMar has discovered a hormone called hepatalin (also known as hepatic insulin-sensitizing substance or HISS hormone) which they believe is the missing link in understanding type 2 diabetes. They are developing approaches to prevent, detect, and treat type 2 diabetes based on this discovery[1][4].
- Therapeutic areas
- Endocrinology
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
Non-profitsindustriesIndigenous communities[1]
Beyond the preview
Go deeper on SciMar.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SciMar.